Takeda‘s Fruzaqla wins UK approval for CRC

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Fruzaqla (fruquintinib) to treat adults with metastatic colorectal cancer (CRC)—to be used when other treatments have not worked. 

This marketing authorization for the oral, chemotherapy-free targeted agent has been granted to Japanese pharma major Takeda (TYO: 4502).

The kinase inhibitor is indicated for the treatment of adult patients with metastatic CRC who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy.